Jazz Pharmaceuticals plc 4

Director Seamus Mulligan received an award of 1,605 restricted stock units of Jazz Pharmaceuticals plc (JAZZ) on August 5, 2026.

On August 5, 2026, director Seamus Mulligan received an award of 1,605 restricted stock units (RSUs) of Jazz Pharmaceuticals plc under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan, with each RSU representing a contingent right to receive one ordinary share upon vesting on July 23, 2027, subject to continued service and certain conditions. The RSUs were granted at no cash cost (reported price $0.00), and following this award Mulligan is reported to beneficially own 1,184,633 ordinary shares directly, plus an additional 101,621 ordinary shares held indirectly through Nerano Pharma Limited, an entity owned and controlled by him and his immediate family. Because no trading price is provided in the filing or snapshot, the dollar value of the grant and the post-transaction ownership value must be inferred qualitatively rather than calculated precisely from this document alone.

Filing Facts

CIK

1232524

Ticker

JAZZ

Form

4

Source Type

fda

Accession

0001536639-26-000004

Alert Tier

4